Published DateClear

Start Date

End Date

Category

• Pipeline2

Organizations

• Bausch + Lomb66
• Eyes On Eyecare51
• Alcon, Inc.46
• American Optometric Association37
• Harrow30
• Glaukos27
• Topcon Healthcare25
• Regeneron24
• Aldeyra Therapeutics20
• Sight Sciences19

Tags

• FDA2
• Stargardt Disease2
• Retina2
• Business Management1
• Gene Therapy1
• Pediatrics1

• Organizations: VeonGen Therapeutics✕

Clear all

Pipeline

FDA grants RMAT designation to VeonGen's Stargardt therapy

Status marks third designation for the VG801, intended to treat patients with biallelic ABCA4 mutations linked to Stargardt disease and related retinal dystrophies

Pipeline

ViGeneron rebrands as VeonGen Therapeutics with new FDA designation

German-based genetic medicine company also receives a Rare Pediatric Disease Designation for its Stargardt disease gene therapy candidate.